Lal S, Laryea E, Thavundayil J X, Nair N P, Negrete J, Ackman D, Blundell P, Gardiner R J
Prog Neuropsychopharmacol Biol Psychiatry. 1987;11(2-3):235-42. doi: 10.1016/0278-5846(87)90066-2.
Apomorphine (Apo), a short acting dopamine (DA) receptor agonist induces penile erections in normal subjects. The erectile response to one or more doses of Apo HCl (0.25, 0.5, 0.75, 1.0 mg sc) or placebo was investigated in eight impotent subjects and penile tumescence monitored using a mercury strain gauge and strip chart recording. Four patients showed a full erection with Apo and one a partial response. Distressing side effects (nausea, sweating) were associated with non-response or partial response. Three responders to Apo were treated with low doses of the long acting DA receptor agonist, bromocriptine (2.5-3.75 mg/d po); all three showed complete recovery of erectile function within two weeks. A subgroup of impotent patients may have impaired central DA function. Testing with Apo may provide a diagnostic and predictive test to identify such patients who may respond to treatment with low doses of bromocriptine or other DA receptor agonist.
阿扑吗啡(Apo)是一种短效多巴胺(DA)受体激动剂,可诱导正常受试者阴茎勃起。在8名阳痿患者中研究了对一剂或多剂盐酸阿扑吗啡(0.25、0.5、0.75、1.0毫克,皮下注射)或安慰剂的勃起反应,并使用水银应变仪和带状图表记录监测阴茎肿胀情况。4名患者使用阿扑吗啡后出现完全勃起,1名患者出现部分反应。令人苦恼的副作用(恶心、出汗)与无反应或部分反应相关。3名对阿扑吗啡有反应的患者接受了低剂量长效DA受体激动剂溴隐亭(2.5 - 3.75毫克/天,口服)治疗;所有3名患者在两周内勃起功能完全恢复。一部分阳痿患者可能存在中枢DA功能受损。用阿扑吗啡进行测试可能提供一种诊断和预测性测试,以识别那些可能对低剂量溴隐亭或其他DA受体激动剂治疗有反应的患者。